Shockwave Therapy in Combination with Avastin and Nab-Paclitaxel for Breast Cancer Treatment
Title of Study: A study to identify the potential effects of extracorporeal shockwave therapy alone and in combination with Avastin
Extracorporeal shockwave therapy (ESWT) has been used in combination with anticancer drugs to increase their effectiveness, but only focused and high-energy shockwave devices have been used in such studies. A new study aims to identify the effects of un-focused ESWT on breast cancer morphology, alone and in combination with the anticancer agent Avastin and Nab-Paclitaxel. Avastin inhibits vascular endothelial growth factor (VEGF), reducing the body’s ability to produce new vasculature, while Nab-Paclitaxel is a mitotic inhibitor that prevents the breakdown of microtubules during cell division. The study found that un-focused ESWT alone reduced cancer cell viability and increased cell death, while in combination with Avastin and Nab-Paclitaxel, it caused an even greater reduction in cancer cell viability and increased cell death. Additionally, ESWT increased the permeability of the cellular structure, allowing the anticancer drugs to penetrate more deeply and increase their concentration within cancerous tissue. This study suggests that un-focused ESWT could be a useful adjunct therapy in breast cancer treatment, especially in combination with Avastin and Nab-Paclitaxel.